MILPROSA (progesterone) by Ferring Pharmaceuticals is clinical pharmacology prometrium capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. Approved for infertility, contraception, in vitro fertilization. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
MILPROSA (progesterone) is an oral micronized progesterone capsule that is chemically identical to naturally occurring ovarian progesterone. It is used across 27+ indications spanning reproductive health (infertility, contraception, IVF, threatened miscarriage), menopausal symptom management, and cancer prevention/treatment. The drug works by binding to progesterone receptors to modulate hormonal function across multiple organ systems.
Product is at peak commercial maturity with 8 linked job openings; commercial teams are actively hiring across sales and account management roles despite approaching LOE in 3.8 years.
CLINICAL PHARMACOLOGY PROMETRIUM Capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. The oral bioavailability of progesterone is increased through micronization. Pharmacokinetics A. Absorption After oral administration of…
Worked on MILPROSA at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Exogenous Progesterone as Ovulation Trigger
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
MILPROSA roles are concentrated in commercial and field-facing functions, reflecting a peak-stage product lifecycle focused on market maximization and account penetration rather than development. Working on MILPROSA offers exposure to women's health franchise leadership, managed care negotiations, and the strategic challenge of defending market share as LOE approaches.
8 open roles linked to this drug